Form 6-K — CureVac N.V.: first participant was dosed in a Phase 1 study of CV2CoV, with GSK (March 30, 2022)
Summary
A Form 6-K report of foreign private issuer filed by CureVac N.V. with the U.S. Securities and Exchange Commission for the month of March, 2022, Commission File Number 001-39446. It states that on March 30, 2022 the company issued a press release announcing that the first participant was dosed in a study of its second-generation COVID-19 mRNA vaccine candidate, CV2CoV, developed in collaboration with GSK. The report says the trial is expected to provide data to evaluate the performance of CureVac's second-generation mRNA backbone. The information is incorporated by reference into Form F-3, File No. 333-259613, and the press release is Exhibit 99.1.
Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used
Cite this document
“Form 6-K — CureVac N.V.: first participant was dosed in a Phase 1 study of CV2CoV, with GSK (March 30, 2022).”
Original at www.sec.gov. Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/sec-cvac-6-k-filed2022-03-30-0001104659-22-040145-3b89131d6b/
, SHA-256 5f1c23b1047955c8e51d8a6bee1511a462abbfead97912d98c0f006ca1627e8e.Full text
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2022 Commission File Number: 001-39446 CureVac N.V. ( Exact Name of Registrant as Specified in Its Charter ) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F | x | Form 40-F | ¨ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Yes | ¨ | No | x Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): Yes | ¨ | No | x On March 30, 2022, CureVac N.V. (the “Company”) issued a press release announcing that the first participant was dosed in a Phase 1 study of COVID-19 second-generation mRNA vaccine candidate, CV2CoV, developed in collaboration with GSK. The clinical trial is expected to provide valuable data to further evaluate the performance of CureVac’s second-generation mRNA backbone, which has the potential to be applied broadly in future vaccines against COVID-19 variants and other pathogens. The information included in this Form 6-K (including Exhibit 99.1, but excluding the statements of the Company’s Chief Development Officer contained in Exhibit 99.1 hereto) is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 ( File No. 333-259613 ). SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CUREVAC N.V. By: | /s/ Franz-Werner Haas, LLD, LLM Chief Executive Officer Date: March 30, 2022 EXHIBIT INDEX EXHIBIT NO. | DESCRIPTION 99.1 | CureVac N.V. Press Release dated March 30, 2022.
File and source
- File
- SEC_CVAC_6-K_filed2022-03-30_0001104659-22-040145.htm
- Size
- 13,969 bytes
- SHA-256
- 5f1c23b1047955c8e51d8a6bee1511a462abbfead97912d98c0f006ca1627e8e
- Original
- www.sec.gov